FY2024 Earnings Estimate for Transcat, Inc. (NASDAQ:TRNS) Issued By HC Wainwright

Transcat, Inc. (NASDAQ:TRNS) – Investment analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Transcat in a report issued on Tuesday, April 16th. HC Wainwright analyst S. Buck now forecasts that the scientific and technical instruments company will earn $1.35 per share for the year, down from their prior estimate of $1.45. HC Wainwright has a “Buy” rating and a $124.00 price objective on the stock. The consensus estimate for Transcat’s current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Transcat’s Q4 2024 earnings at $0.53 EPS.

Transcat (NASDAQ:TRNS) last posted its quarterly earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.03. The business had revenue of $65.17 million for the quarter, compared to analyst estimates of $63.36 million. Transcat had a return on equity of 9.32% and a net margin of 4.16%.

Separately, TheStreet raised shares of Transcat from a “c+” rating to a “b” rating in a research report on Wednesday, January 31st.

Transcat Price Performance

Shares of TRNS opened at $104.71 on Wednesday. The company has a current ratio of 3.37, a quick ratio of 2.81 and a debt-to-equity ratio of 0.01. The stock has a market cap of $924.59 million, a P/E ratio of 80.55 and a beta of 0.59. The stock’s 50-day moving average price is $108.70 and its two-hundred day moving average price is $101.88. Transcat has a 1 year low of $74.89 and a 1 year high of $115.41.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE increased its position in Transcat by 137.9% during the first quarter. US Bancorp DE now owns 345 shares of the scientific and technical instruments company’s stock worth $28,000 after buying an additional 200 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Transcat by 345.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,234 shares of the scientific and technical instruments company’s stock worth $135,000 after buying an additional 957 shares during the last quarter. BNP Paribas Arbitrage SA grew its stake in Transcat by 162.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,626 shares of the scientific and technical instruments company’s stock valued at $92,000 after buying an additional 1,006 shares during the last quarter. Barclays PLC raised its holdings in Transcat by 533.1% in the 4th quarter. Barclays PLC now owns 1,912 shares of the scientific and technical instruments company’s stock valued at $135,000 after acquiring an additional 1,610 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Transcat during the fourth quarter worth approximately $226,000. Institutional investors own 98.34% of the company’s stock.

Insider Activity at Transcat

In other Transcat news, CEO Lee D. Rudow sold 5,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $111.30, for a total transaction of $556,500.00. Following the completion of the transaction, the chief executive officer now owns 108,478 shares in the company, valued at approximately $12,073,601.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Lee D. Rudow sold 2,373 shares of Transcat stock in a transaction that occurred on Saturday, March 30th. The shares were sold at an average price of $111.43, for a total value of $264,423.39. Following the sale, the chief executive officer now directly owns 103,688 shares in the company, valued at $11,553,953.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Lee D. Rudow sold 5,000 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $111.30, for a total transaction of $556,500.00. Following the completion of the sale, the chief executive officer now directly owns 108,478 shares in the company, valued at approximately $12,073,601.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,073 shares of company stock valued at $900,023. 4.20% of the stock is owned by corporate insiders.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.